Corinne Johnson
Stock Analyst at Goldman Sachs
(4.34)
# 1,326
Out of 4,455 analysts
243
Total ratings
55.8%
Success rate
11.8%
Average return
Main Sectors:
Stocks Rated by Corinne Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMLX Amylyx Pharmaceuticals | Maintained: Buy | $20 → $23 | $17.79 | +29.29% | 19 | Jun 18, 2026 | |
| HALO Halozyme Therapeutics | Maintained: Sell | $56 → $57 | $74.96 | -23.96% | 18 | Jun 14, 2026 | |
| RYTM Rhythm Pharmaceuticals | Maintained: Buy | $158 → $159 | $109.84 | +44.76% | 31 | Jun 14, 2026 | |
| TGTX TG Therapeutics | Maintained: Hold | $41 | $55.83 | -26.56% | 21 | Jun 3, 2026 | |
| SNDX Syndax Pharmaceuticals | Maintained: Buy | $34 | $21.31 | +59.55% | 7 | Jun 3, 2026 | |
| IDYA IDEAYA Biosciences | Maintained: Hold | $35 → $36 | $36.74 | -2.01% | 11 | Jun 3, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $182 → $213 | $168.52 | +26.39% | 3 | Jun 2, 2026 | |
| ORIC ORIC Pharmaceuticals | Reiterated: Buy | $15 | $9.53 | +57.40% | 2 | Jun 2, 2026 | |
| BHVN Biohaven | Maintained: Buy | $27 → $25 | $15.83 | +57.93% | 3 | May 28, 2026 | |
| ALT Altimmune | Upgraded: Hold | $2.5 | $2.82 | -11.35% | 8 | Apr 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $28 → $32 | $38.85 | -17.63% | 6 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $38 → $41 | $34.07 | +20.34% | 29 | Apr 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $102 → $101 | $49.71 | +103.18% | 2 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $1 | $1.32 | -24.24% | 17 | Feb 25, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $56 → $82 | $71.96 | +13.95% | 6 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Sell | $32 | $52.31 | -38.88% | 1 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $34.00 | - | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | $28 → $33 | $35.47 | -6.96% | 22 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $3.80 | n/a | 4 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | n/a | $1.86 | n/a | 5 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $9.40 | n/a | 6 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.31 | n/a | 14 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.00 | n/a | 4 | Aug 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $22 | $1.93 | n/a | 1 | Sep 14, 2021 |
Amylyx Pharmaceuticals
Jun 18, 2026
Maintained: Buy
Price Target: $20 → $23
Current: $17.79
Upside: +29.29%
Halozyme Therapeutics
Jun 14, 2026
Maintained: Sell
Price Target: $56 → $57
Current: $74.96
Upside: -23.96%
Rhythm Pharmaceuticals
Jun 14, 2026
Maintained: Buy
Price Target: $158 → $159
Current: $109.84
Upside: +44.76%
TG Therapeutics
Jun 3, 2026
Maintained: Hold
Price Target: $41
Current: $55.83
Upside: -26.56%
Syndax Pharmaceuticals
Jun 3, 2026
Maintained: Buy
Price Target: $34
Current: $21.31
Upside: +59.55%
IDEAYA Biosciences
Jun 3, 2026
Maintained: Hold
Price Target: $35 → $36
Current: $36.74
Upside: -2.01%
Neurocrine Biosciences
Jun 2, 2026
Initiated Coverage: Buy
Price Target: $182 → $213
Current: $168.52
Upside: +26.39%
ORIC Pharmaceuticals
Jun 2, 2026
Reiterated: Buy
Price Target: $15
Current: $9.53
Upside: +57.40%
Biohaven
May 28, 2026
Maintained: Buy
Price Target: $27 → $25
Current: $15.83
Upside: +57.93%
Altimmune
Apr 24, 2026
Upgraded: Hold
Price Target: $2.5
Current: $2.82
Upside: -11.35%
Apr 15, 2026
Rated: Hold
Price Target: $28 → $32
Current: $38.85
Upside: -17.63%
Apr 15, 2026
Maintained: Buy
Price Target: $38 → $41
Current: $34.07
Upside: +20.34%
Mar 16, 2026
Maintained: Buy
Price Target: $102 → $101
Current: $49.71
Upside: +103.18%
Feb 25, 2026
Reiterated: Sell
Price Target: $1
Current: $1.32
Upside: -24.24%
Jan 12, 2026
Maintained: Buy
Price Target: $56 → $82
Current: $71.96
Upside: +13.95%
Dec 4, 2025
Initiated Coverage: Sell
Price Target: $32
Current: $52.31
Upside: -38.88%
Jul 18, 2025
Maintained: Buy
Price Target: n/a
Current: $34.00
Upside: -
Jul 10, 2025
Initiated Coverage: Hold
Price Target: $28 → $33
Current: $35.47
Upside: -6.96%
Jul 31, 2024
Maintained: Buy
Price Target: n/a
Current: $3.80
Upside: n/a
Jul 24, 2024
Reiterated: Sell
Price Target: n/a
Current: $1.86
Upside: n/a
Jun 18, 2024
Maintained: Hold
Price Target: n/a
Current: $9.40
Upside: n/a
Nov 14, 2023
Reiterated: Hold
Price Target: n/a
Current: $1.31
Upside: n/a
Aug 7, 2023
Reiterated: Buy
Price Target: n/a
Current: $5.00
Upside: n/a
Sep 14, 2021
Downgraded: Hold
Price Target: $22
Current: $1.93
Upside: n/a